

# Prevalence, genetic diversity of and factors associated with ESBL-producing Enterobacterales carriage in residents of French nursing homes

M. Broussier, H. Gbaguidi-Haore, F. Rachidi-Berjamy, X. Bertrand, C.

Slekovec

## ▶ To cite this version:

M. Broussier, H. Gbaguidi-Haore, F. Rachidi-Berjamy, X. Bertrand, C. Slekovec. Prevalence, genetic diversity of and factors associated with ESBL-producing Enterobacterales carriage in residents of French nursing homes. Journal of Hospital Infection, 2019, 10.1016/j.jhin.2019.12.008 . hal-02541483

## HAL Id: hal-02541483 https://hal.science/hal-02541483v1

Submitted on 22 Aug2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Version of Record: https://www.sciencedirect.com/science/article/pii/S0195670119305298 Manuscript\_5ea97efa5ba5ae860cf36c83bc4bf0db

## Prevalence, genetic diversity of- and factors associated with ESBL-producing Enterobacteriaceae carriage in residents of French Nursing Homes

Broussier M<sup>1</sup>, Gbaguidi-Haoré H<sup>1,2</sup>, Rachidi-Berjamy F<sup>3</sup>, Bertrand X<sup>1,2</sup>, Slekovec C.<sup>2,3</sup>

<sup>1</sup> Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, Besançon, France

<sup>2</sup> UMR 6249 Chrono-environnement, Université de Bourgogne-Franche-Comté,

Besançon, France

<sup>3</sup> CPias Bourgogne-Franche-Comté, Centre Hospitalier Régional Universitaire,

Besançon, France

\* Corresponding author: Céline Slekovec

Hygiène Hospitalière, Centre Hospitalier Régional Universitaire, 3 boulevard Fleming,

Besançon, Cedex 25030, France.

Tel: +33381668553

Fax: +33381668558

E-mail: cslekovec@chu-besancon.fr

Word count: 3249

Running tittle: MDR-Enterobacteriaceae in nursing homes

**Key words**: *Escherichia coli, Klebsiella pneumoniae*, ESBL, epidemiology, risk factors, nursing homes, elderly

### Abstract

**Objective**: To determine the prevalence and genotypic characteristics of extendedspectrum  $\beta$ -lactamase-producing *Enterobacteriaceae* (ESBLE) and Carbapenemaseproducing *Enterobacteriaceae* (CPE) in Nursing Homes (NHs) in a French region. Risk factors associated with their carriage were also investigated.

**Methods:** A point-prevalence survey was proposed from November 2017 to June 2018 to NHs of our region. Volunteer residents were screened for ESBLE and CPE carriage. We genotyped *E. coli* and *K. pneumoniae* isolates using, MLST, PFGE and phylogrouping (only for *E. coli*). Collective and individual data were analyzed by random-effects logistic regression.

**Results:** The study was conducted in 18 nursing homes and included 262 patients. Fifty-two of them (19.8%) carried at least one ESBLE, corresponding to 56 isolates (42 *E. coli*, 11 *K. pneumoniae*, and 3 others) while no CPE was detected. A majority (27/42) of ESBL-*E. coli* belonged to phylogroup B2 and ST131 was overrepresented in this subset (21/27). PFGE analysis revealed ST131 cross-transmission within NHs. Regarding ESBL-*K. pneumoniae*, 9 out of 11 isolates belonged to ST663 and PFGE suggested the diffusion of the clone in six NHs. Significant individual risk factors for colonization by ESBLE were: use of non-private toilettes, previous antibiotic use and recent history of hospitalization. Significant collective protective factors were proper compliance with gloves use and support of the NH by a healthcare facility.

**Conclusion:** This study shows that NHs within our region are an important reservoir of ESBLE, whereas no residents were CPE carrier. ESBLE control in NHs should focus on antibiotic stewardship and excreta management policies.

#### Introduction

Antimicrobial resistance is a worldwide problem and is projected to surpass cancer as the leading cause of death by 2050 [1]. Of particular interest, extended-spectrum β-lactamase-producing *Enterobacteriaceae* (ESBLE) has become a major European public health concern in the last two decades [2]. For instance, the incidence of infections caused by ESBLE has increased dramatically in French hospitals, and Escherichia coli has become the most frequent species among ESBLE (60%), before Klebsiella pneumoniae (25%) [3]. There is rising concern regarding Nursing Homes (NHs) which are considered as reservoirs of ESBLE, because the residents frequently require medical care and antimicrobial treatments [4]. In addition, the recent emergence of carbapenemase-producing Enterobacteriaceae (CPE) also represents a significant worldwide threat to public health and some studies from Southern Europe have reported significant prevalence of CPE carriage in NH or longterm-care facilities residents [5, 6]. However, the prevalence of ESBLE and CPE carriage among residents of French NHs remains poorly described. In this context, the objective of our study was to assess the prevalence of ESBLE and CPE carriage in residents of NHs of Franche-Comté, a region in eastern France. We further investigated the molecular characteristics of these multi-drug-resistant isolates as well as collective and individual risk factors associated with their carriage.

## Methods

## Study design, setting and participants

A cross-sectional prevalence survey was performed one day from November 2017 to June 2018, in NHs from Franche-Comté (France). A two stage random sampling method was used. We randomly selected 50 NHs out of 135 eligible to participate in the study. In NHs volunteered to participate, from 20 to 35 residents per NH, depending on the housing capacity, were also randomly selected. Residents with inability to express their participation agreement were excluded. Individual residents elected to participate in the study were appropriately informed of the study protocol by the medical coordinator. Their oral approval was noticed in their medical record. The study was approved by the ethical committee 'Comité d'Etude Clinique' of the Besançon university hospital, Besançon, France, Reference: 2017-A00276-47.

#### Microbiological analysis

Rectal bacterial samples were collected using a rectal swab or with fresh stool (Fecal swab, Copan Diagnostics, Brescia, Italy). Samples were all analyzed in hygiene laboratory of Besançon University hospital within 72 hours after collection. Samples were streaked onto ChromiD ESBL and ChromID<sup>®</sup> CARBA SMART agar (Biomérieux, Marcy-l'Etoile, France) and incubated aerobically at 35 ± 2°C for 24h, in accordance with the manufacturer's instructions. Isolates obtained were identified to the species level using a MALDI-TOF mass spectrometry (Microflex LT; Bruker Daltonik GmbH. Bremen, Germany) according manufacturer's to the recommendations. For all ESBL-suspected Enterobacteriaceae isolates, the presence of ESBL was confirmed using a double-disk synergy test according to the EUCAST recommendations (http://www.eucast.org/clinical breakpoints/). ESBL

genes were identified by PCR and sequencing. After screening all samples with consensus primers targeting *bla*<sub>CTX-M</sub>, we carried out more specific amplifications, beginning with primers targeting different groups of CTX-M (*bla*<sub>CTX-M</sub> group 1 *bla*<sub>CTX-M</sub> group 9, *bla*<sub>CTX-M</sub> group 2). Then, we tested for the presence of *bla*<sub>SHV</sub> or *bla*<sub>TEM</sub> genes [7]. All ESBL-producing *E. coli* isolates were typed by phylogrouping as previously described [8]. MLST was performed on all ESBL-producing *E. coli* and *K. pneumoniae* isolates according to protocols previously described [9]. The MLST website (http://pubmlst.org/) was used for the assignment of allele numbers and ST. PFGE was used to assess the clonal diversity within each ST using *Xba*l digestion. Pulsotypes (PTs) were defined according to international recommendations [10]. For a given bacteria, isolates which shared similar PT, and recovered from the same NH, were thought to be cross-transmitted.

#### Data collection

Two trained infection control practitioners collected all data using standardized questionnaires for collective and individual variables.

#### Facility questionnaire

Numerical variables collected included: a French index to evaluate the average level of dependency of NH residents (GMP), housing capacity and number of physicians participating to care of the residents. Categorical variables collected included: sectorization (specific staff allocated to units of the NH during day and night shifts), whether physicians had a list of recommended antibiotics and antimicrobial stewardship guidelines, whether the NH was linked to larger healthcare institution, existence of an in-house pharmacy, hygiene protocols regarding ESBLE and CPE or

route for waste disposal, whether the NH benefit intervention of an infection control nurse of the regional mobile team, availability of items related to hygiene (bedpan washer disinfectors, near patient alcohol-based hand-rub, single-use gloves and aprons) and frequency of use, staff training in standard precautions and hand hygiene and information to residents regarding hand hygiene.

### Resident questionnaire

Individual data collected were: age, sex, a French index to evaluate the level of dependency (GIR varying from 1 to 6, an index close to 1 indicates a high level of dependency), duration of stay, single or shared bedroom, bed rest, how urine and feces were eliminated (their own bathroom, shared bathroom, commode chair, use of incontinence products), medical history including diabetes, immunodeficiency, urinary and fecal incontinence, presence of invasive medical devices, antibiotic treatment in the previous 6 months and hospitalization in the past 12 months.

## Statistical analysis

Descriptive statistics were displayed for both nursing homes and individual residents. Univariate comparison between groups was done using Pearson's Chi-square test or Fisher's exact test for categorical variables. We compared numerical variables by carrying out Student's t-test or the Mann-Whitney U test, as appropriate. Multivariate analysis was conducted using random-effects logistic regression model taking into account the clustered structure of data (residents nested within NHs). The binary outcome variable was ESBLE positivity on stool sample. Explanatory variables were selected using stepwise regression through backward elimination procedure. All explanatory variables that showed a p value of less than 0.10 in the univariate analysis were considered for the multivariate analysis. Analyses were conducted using the software package Stata, version 14.1 (Stata Corp., College Station, TX, USA). A p value of less than 0.05 was considered significant.

## Results

#### Participation

Out of the 50 NHs randomized, 18 (36.0%) volunteered to participate to the study. In these NH, 776 residents met the inclusion criteria. After randomization and record of participation agreement, 262 residents, with complete data and sample, were included, representing an average of 14.5 residents per NH (range: 3 to 33). The flow chart of the study is presented in the Figure 1. Data collected on NHs and residents are displayed in Table I and Table II, respectively.

### Microbiological analysis

Fifty-two of the residents (19.8% [CI: 12.5-27.1]) carried at least one ESBLE, corresponding to 56 isolates (42 *E. coli*, 11 *K. pneumoniae*, 2 *Citrobacter farmer* and 1 *Morganella morganii*) while no CPE was detected. The overall ESBLE prevalence in NHs varied from 0 to 43.8%, four of them had no ESBLE carriers amongst the 5 to 17 residents tested, while one had seven carriers amongst 16 residents tested.

Four residents carried 2 ESBLE (3 *E. coli* and *K. pneumoniae*, 1 *E. coli* and *M. morganii*). A majority (27/42) of ESBL *E. coli* belonged to phylogroup B2, the others were distributed in phylogroup D (n=8), phylogroup A (n=4) and phylogroup B1 (n=3). ST131 was overrepresented in the phylogroup B2 (21 out of the 27 isolates). The 21 ST131 isolates were recovered in only five NHs (from one to nine cases per NH) and PFGE analysis revealed ST131 cross-transmission within NHs. In two NHs, all of the isolates (n=4 and n=6 respectively) belonged to the same PFGE pattern. In the NH where nine ST131 isolates were identified, isolates clustered in four PFGE patterns (with six isolates sharing the same PFGE pattern). It should be noted that no PFGE

patterns of ST131 were shared by residents from different NHs. All the ESBLs identified in ST131 isolates were of CTX-M type with a predominance of CTX-M-27 (n=9) and CTX-M-15 (n=8). In phylogroup D, CC69 and ST362 were identified for three and two isolates, respectively with no evidence of cross-transmission. Regarding ESBL producing *K. pneumoniae*, 9 out of 11 belong to ST663; were CTX-M-15 producers and belonged to the same PFGE pattern, but were detected in residents from six different NHs. Genotyping data are summarized in Table III.

### Statistical analysis

The results of univariate and multivariate analysis are presented in Table IV. The risk of carrying ESBLE was increased by not using the resident's own bathroom (OR = 2.32, CI [1.17-4.57], p = 0.015) and history of antibiotic use in the past 6 months (OR = 2.32, CI [1.20-4.49], p = 0.012) or hospitalization in the past 12 months (OR = 2.04, CI [1.03-4.03], p = 0.041). Protective factors were systematic use of single-use gloves whenever expected (OR = 0.25, CI [.011-0.58], p = 0.001) and the nursing home being linked to a larger healthcare institution (OR = 0.41, CI [0.19-0.87], p = 0.020).

#### Discussion

This study shows that NHs in our region are an important reservoir of ESBLE with almost 20% carriage amongst residents. This figure is in line with the pooled prevalence of ESBLE reported by Flokas and colleagues in their systematic review (i.e. 18% in European NHs) despite considerable geographical variability [11]. We also observed huge variability within NHs included in this study mainly due to intra-NHs outbreaks of the pandemic clonal group ST131. Indeed, our survey reveals occult outbreaks of ST131 specific pulsotypes in 3 NHs; involving C1-CTX-M-27 and C2-CTX-M-15 clades. The latter is the predominant ST131 cluster, responsible for the worldwide spread of CTX-M-15 [12] and has been first detected in our region in 2006 [13]. C1-CTX-M-27 clade emerged in 2010 in our university hospital [13]. This cluster initially described in Japan in 2004 [14], has spread secondarily in Europe where it has been notably identified in children [15] and in adult inpatients [16]. To the best of our knowledge, this report is the first to detect C1-CTX-M-27 cluster in French NHs.

ST131 clonal group, for which we observed a carriage rate of 8% in that study, has been frequently associated to elderly and NHs with carriage rates varying from 4 to 20% of the residents [17, 18]. The specific success of ESBL ST131 over other ESBL producing *E. coli* clones in NHs may be due to prolonged colonization. Indeed, Overdevest and colleagues demonstrated in Dutch NHs that half-time carriage was significantly longer for ESBL ST131 (13 months) than for other ESBL producing *E. coli* (2-3 months) [19].

PFGE results of ESBL producing *K. pneumonia*e strongly suggest spread of isolates of ST663 in NHs from a common reservoir. This ST has been only reported in Spanish hospitals associated to OXA-48 production [20]; it is a single-locus variant of ST405, which was responsible for an outbreak in the university hospital of our region (Personal data X Bertrand). Consequently, it is very likely that this strain originated from the university hospital and imported in NHs via colonized patients. It should be noticed that one of the residents was carrier of the emerging pandemic ST307 lineage. A recent phylogenetic analysis using whole genome sequencing showed that this has emerged in the 1990s, has spread globally intimately associated with a conserved plasmid containing the *bla*CTX-M-15 ESBL gene and several other resistance genes [21]. ST307 can also acquire and disseminate carbapénémases [21]. None of the residents were CPE carrier, this reflects that our region remains an area with very low incidence of CPE, to date [22].

Risk analysis in the current study indicated that previous hospitalization, previous antibiotic exposure and the use of non-private toilettes were associated with high probability of ESBLE carriage. Acute care hospitals and NHs seem to act as communicating vessels for ESBLE as mentioned by Latour and colleagues [23] and history of previous hospitalization as well as previous antibiotic use were frequently identified as risk factors for ESBLE carriage in NHs [11]. Excreta management had also been identified in person-to-person transmission of ESBLE [24]. Our analysis stresses the importance of individualized toilets for residents who are able to use it. This study revealed a significant protective impact of proper observance of single-use gloves too, underlining the need of proper practices for excreta management. However, the relevance of the use of gloves was not evaluated and misuse of gloves,

like overuse, can increase the risk of cross transmission via contaminated gloved hands [25]. Other risk factors such as history of invasive devices, underlying comorbidities that are frequently reported in the literature [11] to be associated with ESBLE carriage in NH residents were not found in our study, probably due to insufficient number of residents included in the present surveillance. In accordance to previous studies [16], level of mobility and gender were not associated to ESBLE carriage.

We do acknowledge that this study had several limitations. First, the study design (point prevalence survey) did not take into account the dynamics of ESBLE epidemiology. Second, the low proportion of NHs that agreed to participate to the study limits the number of residents included and potentially hinder the identification of risk factors associated to ESBLE carriage.

## Conclusion

This study shows that NHs within our region are an important reservoir of ESBLE, that special attention should be given to pandemic ST131 *E. coli* and *K. pneumonia*e clones and that ESBLE control in NHs should focus on antibiotic stewardship and excreta management policies.

**Acknowledgements**: The authors would like to acknowledge all the nursing homes included in this study, their healthcare workers for their involvement and residents for their participation.

## Declaration of interest: None

**Funding source**: This work was supported by the GIRCI-Est awarded following the 2016 Young Researchers call.

**Author contributions**: Conceived and designed the experiments: XB, CBS. Performed the experiments: MB, CBS, FB. Analysed the data: CBS, HGH, XB, MB. Wrote the paper: CBS, XB.

#### References

[1] Jim O'Neill. The review on antimicrobial resistance. 2015.

[2] Cassini A, Plachouras D and Monnet DL. Attributable deaths caused by infections with antibioticresistant bacteria in France - Authors' reply. Lancet Infect Dis. 2019;19(2):129-30.

[3] Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. National multidrugresistant bacteria (MDRB) surveillance in France through the RAISIN network: a 9 year experience. J Antimicrob Chemother. 2013;68(4):954-9.

[4] Willemsen I, Nelson J, Hendriks Y, Mulders A, Verhoeff S, Mulder P, et al. Extensive dissemination of extended spectrum beta-lactamase-producing Enterobacteriaceae in a Dutch nursing home. Infect Control Hosp Epidemiol. 2015;36(4):394-400.

[5] Ruiz-Garbajosa P, Hernandez-Garcia M, Beatobe L, Tato M, Mendez MI, Grandal M, et al. A singleday point-prevalence study of faecal carriers in long-term care hospitals in Madrid (Spain) depicts a complex clonal and polyclonal dissemination of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2016;71(2):348-52.

[6] Nucleo E, Caltagirone M, Marchetti VM, D'Angelo R, Fogato E, Confalonieri M, et al. Colonization of long-term care facility residents in three Italian Provinces by multidrug-resistant bacteria. Antimicrob Resist Infect Control. 2018;7:33.

[7] Brechet C, Plantin J, Sauget M, Thouverez M, Talon D, Cholley P, et al. Wastewater treatment plants release large amounts of extended-spectrum beta-lactamase-producing Escherichia coli into the environment. Clin Infect Dis. 2014;58(12):1658-65.

[8] Clermont O, Christenson JK, Denamur E and Gordon DM. The Clermont Escherichia coli phylotyping method revisited: improvement of specificity and detection of new phylo-groups. Environ Microbiol Rep. 2013;5(1):58-65.

[9] Diancourt L, Passet V, Verhoef J, Grimont PA and Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol. 2005;43(8):4178-82.

[10] Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233-9.

[11] Flokas ME, Alevizakos M, Shehadeh F, Andreatos N and Mylonakis E. Extended-spectrum betalactamase-producing Enterobacteriaceae colonisation in long-term care facilities: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;50(5):649-56.

[12] Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, Khanh Nhu NT, Roberts LW, Stanton-Cook M, et al. Erratum for Ben Zakour et al., Sequential Acquisition of Virulence and Fluoroquinolone Resistance Has Shaped the Evolution of Escherichia coli ST131. MBio. 2016;7(3).

[13] Sauget M, Cholley P, Vannier A, Thouverez M, Nicolas-Chanoine MH, Hocquet D, et al. Trends of extended-spectrum beta-lactamase-producing Escherichia coli sequence type 131 and its H30 subclone in a French hospital over a 15-year period. Int J Antimicrob Agents. 2016;48(6):744-7.
[14] Matsumura Y, Pitout JD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, et al. Global Escherichia

coli Sequence Type 131 Clade with blaCTX-M-27 Gene. Emerg Infect Dis. 2016;22(11):1900-7.

[15] Birgy A, Levy C, Nicolas-Chanoine MH, Cointe A, Hobson CA, Magnan M, et al. Independent Host
Factors and Bacterial Genetic Determinants of the Emergence and Dominance of Escherichia coli
Sequence Type 131 CTX-M-27 in a Community Pediatric Cohort Study. Antimicrob Agents Chemother.
2019;63(7).

[16] Ghosh H, Doijad S, Falgenhauer L, Fritzenwanker M, Imirzalioglu C and Chakraborty T. blaCTX-M-27-Encoding Escherichia coli Sequence Type 131 Lineage C1-M27 Clone in Clinical Isolates, Germany.
Emerg Infect Dis. 2017;23(10):1754-6.

[17] Arvand M, Moser V and Pfeifer Y. Prevalence of extended-spectrum-beta-lactamase-producing
 Escherichia coli and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse,
 Germany. J Antimicrob Chemother. 2013;68(11):2686-8.

[18] Rodrigues C, Machado E, Fernandes S, Peixe L and Novais A. Different Escherichia coli B2-ST131 clades (B and C) producing extended-spectrum beta-lactamases (ESBL) colonizing residents of Portuguese nursing homes. Epidemiol Infect. 2017;145(15):3303-6.

[19] Overdevest I, Haverkate M, Veenemans J, Hendriks Y, Verhulst C, Mulders A, et al. Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014. Euro Surveill. 2016;21(42).

[20] Oteo J, Hernandez JM, Espasa M, Fleites A, Saez D, Bautista V, et al. Emergence of OXA-48producing Klebsiella pneumoniae and the novel carbapenemases OXA-244 and OXA-245 in Spain. J Antimicrob Chemother. 2013;68(2):317-21.

[21] Wyres KL, Hawkey J, Hetland MAK, Fostervold A, Wick RR, Judd LM, et al. Emergence and rapid global dissemination of CTX-M-15-associated Klebsiella pneumoniae strain ST307. J Antimicrob Chemother. 2019;74(3):577-81.

[22] Emery A, Jeanvoine A, Bailly P, Gbaguidi-Haore H, Hocquet D and Bertrand X. Management of carbapenemase-producing Enterobacteriaceae in a low incidence area: A six-year experience in a university hospital. Infect Control Hosp Epidemiol. 2019;40(8):936-8.


[23] Latour K, Huang TD, Jans B, Berhin C, Bogaerts P, Noel A, et al. Prevalence of multidrug-resistant organisms in nursing homes in Belgium in 2015. PLoS One. 2019;14(3):e0214327.

[24] N'Guyen TTH, Bourigault C, Guillet V, Buttes AGD, Montassier E, Batard E, et al. Association between excreta management and incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae: role of healthcare workers' knowledge and practices. J Hosp Infect.

#### 2019;102(1):31-6.

[25] Picheansanthian W and Chotibang J. Glove utilization in the prevention of cross transmission: a systematic review. JBI Database System Rev Implement Rep. 2015;13(4):188-230.

Figure 1. Flow chart of the study.



NH: nursing home; 3GC: third generation cephalosporin; ESBLE: extended-spectrum-betalactamase-producing *Enterobacteriaceae*; CPE: carbapénémase-producing *Enterobacteriaceae*. Table I. Characteristics of nursing homes (N=18)

|   | N (%)     | Median (min-max |
|---|-----------|-----------------|
| GMP   |           | 729.5 (568-840) |
| Housing capacity  |           | 78.9 (24-236)   |
| Number of eligible residents per NH                           |           | 30.0 (9-197)    |
| Number of volunter residents per NH                           |           | 15.5 (3-33)     |
| Number of physicians  |           | 9.5 (1-31)      |
| Sectorisation of care during the day                          | 11 (61.1) |                 |
| Sectorisation of care during the night                        | 6 (33.3)  |                 |
| Existence of a preferential list of ATB                       | 8 (44.4)  |                 |
| Existence of an institutional ATB policy                      | 13 (72.2) |                 |
| NH linked to a larger healthcare institution                  | 8 (44.4)  |                 |
| Existence of an in-house pharmacy                             | 9 (50.0)  |                 |
| Intervention of a hygienist nurse of the regional mobile team | 13 (72.2) |                 |
| Existence of a route for waste disposal                       | 18 (100)  |                 |
| Existence of protocols regarding ESBLE                        | 11 (61.1) |                 |
| Existence of protocols regarding CPE                          | 11 (61.1) |                 |
| Bedpan washer disinfector                                     | 6 (33.3)  |                 |
| ABHR available close to the care                              | 18 (100)  |                 |
| Single-use gloves available                                   | 18 (100)  |                 |
| Sigle-use apron available                                     | 18 (100)  |                 |
| Staff training in universal hygiene precautions               | 15 (83.3) |                 |
| staff training in hand hygiene                                | 16 (88.9) |                 |
| information to resident regarding hand hygiene                | 11 (61.1) |                 |

GMP : a French index to assess the average level of dependence of NH residents; NH: nursing home; ATB : antibiotics; ESBLE: extended-spectrum-beta-lactamase producing *Enterobacteriaceae*; CPE: carbapenemase-producing *Enterobacteriaceae*; ABHR: alcool-based hand-rub

|  | ESBLE carriers         | Non-ESBLE carriers  |
|--|------------------------|---------------------|
|  | N=52                   | N=210               |
|  | Proportion n (%)       | Proportion n (%)    |
|  | or Median (min-max)    | or Median (min-max) |
| Sex                                    |                        |                     |
| Female                                 | 40 (76.9)              | 163 (77.6)          |
| Male                                   | 12 (23.1)              | 47 (22.4)           |
| Age                                    | 88 (62-100)            | 89 (62-100)         |
| GIR <3                                 | 37 (71.2)              | 118 (56.2)          |
| Duration of stay (in days)             | 1030 (20-4802)         | 779.5 (19-5790)     |
| Single bedroom                         | 43 (82.7)              | 156 (74.3)          |
| Way to excreta disposal                |                        |                     |
| Private bathroom                       | 27 (51.9)              | 143 (68.1)          |
| Shared bathroom                        | 8 (15.4)               | 56 (26.7)           |
| Commode chair                          | 15 (28.9)              | 54 (25.7)           |
| Incontinence pad                       | 47 (90.4)              | 170 (81.0)          |
| Medical history                        |                        |                     |
| Immunodeficiency                       | 4 (7.7)                | 12 (5.7)            |
| Diabetes                               | 4 (7.7)<br>6 (11.5)    | 29 (13.8)           |
| Urinary incontinence                   | 46 (88.5)              | 153 ( 72.9)         |
| Fecal incontinence                     | 48 (88.5)<br>31 (59.6) | 100 ( 47.6)         |
| Bed rest                               | 5 (9.6)                | 16 (7.6)            |
| Previous carriage of ESBLE or CPE (n=  | 4/37 (10.8)            | 5/169 (3.0)         |
| 206)                                   | 4/37 (10.0)            | 5/105 (5.0)         |
| Exposure to an invasive medical device | 3 (5.8)                | 13 (6.2)            |
| Digestive tract device                 | 0                      | 1 (0.5)             |
| Urinary tract device                   | 1 (3.1)                | 7 (3.3)             |
| Previous exposure to ATB within 6      | 30/50 (60.0)           | 76/203 (37.4)       |
| months (n=253)                         |                        |                     |
| Fluoroquinolones                       | 2 (4.0)                | 8 (3.9)             |
| Amoxicillin                            | 10 (20.0)              | 18 (8.9)            |
| Amoxicillin-clavulanate                | 5 (10.0)               | 19 (9.4)            |
| 3GC                                    | 10 (20.0)              | 21 (10.3)           |
| Carbapenems                            | 0                      | 0                   |

Table II. Characteristics of patients according to their carrier statute (N=262)

|   | Other | 10 (20.0) | 31 (15.3) |
|---|-------|-----------|-----------|
| Previous hospitalization within 12 months |       | 24 (46.2) | 50 (23.8) |

GIR: level of dependency French index; ESBLE: extended-spectrum-beta-lactamase producing *Enterobacteriaceae*; CPE: carbapenemase-producing *Enterobacteriaceae*; ATB: antibiotics; 3GC: third generation cephalosporins.

| Isolate | NH   | Resident |               |            |      |     |          | PFGE |
|---------|------|----------|---------------|------------|------|-----|----------|------|
| no      | no   | no       | Specie        | Phylogroup | ST   | CC  | ESBL     | no   |
| 1       | 1/19 | 1/19/002 | E. coli       | B2         | 1618 | 73  | CTX-M-17 |      |
| 2       | 6/01 | 6/01/007 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 5    |
| 3       | 6/01 | 6/01/008 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 5    |
| 4       | 6/01 | 6/01/015 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 5    |
| 5       | 6/01 | 6/01/016 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 5    |
| 6       | 7/63 | 7/63/004 | E. coli       | B2         | 141  | 141 | CTX-M-14 |      |
| 7       | 4/26 | 4/26/007 | E. coli       | B1         | 708  | 469 | CTX-M-1  | 8    |
| 8       | 4/26 | 4/26/008 | E. coli       | B1         | 708  | 469 | CTX-M-1  | 8    |
| 9       | 4/26 | 4/26/011 | E. coli       | D          | 362  |     | CTX-M-1  |      |
| 10      | 4/26 | 4/26/019 | E. coli       | B2         | 372  |     | CTX-M-1  |      |
| 11      | 7/64 | 7/64/002 | E. coli       | B2         | 73   | 73  | CTX-M-3  |      |
| 12      | 7/64 | 7/64/004 | E. coli       | B1         | 443  |     | CTX-M-15 |      |
| 13      | 8/1  | 8/01/086 | E. coli       | D          | 648  |     | CTX-M-15 |      |
| 14      | 8/2  | 8/02/001 | E. coli       | D          | 69   | 69  | CTX-M-1  |      |
| 15      | 8/2  | 8/02/007 | E. coli       | B2         | 131  | 131 | CTX-M-1  | 6    |
| 16      | 9/1  | 9/01/003 | E. coli       | А          | 23   | 23  | CTX-M-14 |      |
| 17      | 9/1  | 9/01/006 | E. coli       | D          | 362  |     | CTX-M-14 |      |
| 18      | 9/1  | 9/01/007 | E. coli       | А          | 23   | 23  | CTX-M-14 |      |
| 19      | 8/3  | 8/03/004 | E. coli       | B2         | 131  | 131 | CTX-M-1  |      |
| 20      | 8/3  | 8/03/005 | E. coli       | D          | 69   | 69  | CTX-M-1  |      |
| 21      | 8/3  | 8/03/010 | E. coli       | D          | 106  | 69  | CTX-M-1  |      |
| 22      | 9/3  | 9/03/001 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 23      | 9/3  | 9/03/002 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 24      | 9/3  | 9/03/005 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 4    |
| 25      | 9/3  | 9/03/008 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 26      | 9/3  | 9/03/013 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 27      | 9/3  | 9/03/014 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 28      | 9/3  | 9/03/019 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 2    |
| 29      | 9/3  | 9/03/023 | E. coli       | B2         | 131  | 131 | CTX-M-27 | 3    |
| 30      | 9/3  | 9/03/026 | E. coli       | B2         | 131  | 131 | CTX-M-1  | 7    |
| 31      | 9/4  | 9/04/005 | E. coli       | B2         | 104  |     | CTX-M-14 |      |
| 32      | 9/4  | 9/04/008 | E. coli       | B2         | 127  |     | CTX-M-15 |      |
| 33      | 9/4  | 9/04/011 | E. coli       | D          | 59   | 59  | CTX-M-14 |      |
| 34      | 9/4  | 9/04/014 | E. coli       | А          | 23   | 23  | CTX-M-14 |      |
| 35      | 9/4  | 9/04/016 | E. coli       | А          | 23   | 23  | CTX-M-14 |      |
| 36      | 9/5  | 9/05/001 | E. coli       | D          | 38   | 38  | CTX-M-15 |      |
| 37      | 9/5  | 9/05/012 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 38      | 9/5  | 9/05/013 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 39      | 9/5  | 9/05/016 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 40      | 9/5  | 9/05/018 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 41      | 9/5  | 9/05/024 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 42      | 9/5  | 9/05/026 | E. coli       | B2         | 131  | 131 | CTX-M-15 | 1    |
| 43      | 1/54 | 1/54/003 | K. pneumoniae |            | 663  |     | CTX-M-15 | 2    |
| 44      | 1/54 | 1/54/008 | K. pneumoniae |            | 663  |     | CTX-M-15 | 2    |
| 45      | 8/1  | 8/01/068 | K. pneumoniae |            | 663  |     | CTX-M-15 | 2    |
| 46      | 8/2  | 8/02/001 | K. pneumoniae |            | 663  |     | CTX-M-15 | 2    |
| 47      | 8/2  | 8/02/002 | K. pneumoniae |            | 663  |     | CTX-M-15 | 2    |

Table III. Summary table of the genotypic and phenotypic characteristics of bacterial isolates

| Isolate | NH  | Resident | Specie        | Phylogroup | ST   | СС | ESBL     | PFGE |
|---------|-----|----------|---------------|------------|------|----|----------|------|
| no      | no  | no       | Opecie        | Thylogroup | 51   | 00 | LODL     | no   |
| 48      | 8/2 | 8/02/014 | K. pneumoniae |            | 663  |    | CTX-M-15 | 2    |
| 49      | 9/3 | 9/03/023 | K. pneumoniae |            | 663  |    | CTX-M-15 | 2    |
| 50      | 9/4 | 9/04/003 | K. pneumoniae |            | 663  |    | CTX-M-15 | 2    |
| 51      | 9/4 | 9/04/016 | K. pneumoniae |            | 3455 |    | CTX-M-14 | 3    |
| 52      | 9/5 | 9/05/018 | K. pneumoniae |            | 307  |    | CTX-M-15 | 1    |
| 53      | 9/5 | 9/05/009 | K. pneumoniae |            | 663  |    | CTX-M-15 | 2    |
| 54      | 9/2 | 9/02/004 | C. farmeri    |            |      |    |          |      |
| 55      | 9/2 | 9/02/016 | C. farmeri    |            |      |    |          |      |
| 56      | 9/4 | 9/04/006 | M. morgannii  |            |      |    |          |      |

NH: nursing home; ST: sequence type; CC: clonal complex; ESBL: extended spectrum betalactamase; PFGE: pulsed field gel electrophoresis.

|  | Univariate analysis |            | Multivar | iate analysis |
|--|---------------------|------------|----------|---------------|
|  | OR                  | 95% CI     | OR       | 95% CI        |
| Collective variables                         |                     |            |          |               |
| Housing capacity 50-100 residents            | 4.71                | 1.00-22.29 |          |               |
| Sectorisation of care during the night       | 0.42                | 0.19-0.92  |          |               |
| NH linked to a larger healthcare institution | 0.43                | 0.21-0.90  | 0.41     | 0.19-0.87     |
| Existence of an in-house pharmacy            | 0.49                | 0.23-1.03  |          |               |
| Existence of a preferential list of ATB      | 0.47                | 0.22-1.02  |          |               |
| Systematic use of single-use gloves          | 0.39                | 0.16-0.96  | 0.25     | 0.11-0.58     |
| Staff training in hand hygiene               | 4.59                | 0.93-22.6  |          |               |
| Individual variables                         |                     |            |          |               |
| GIR < 3                                      | 2.04                | 0.99-4.18  |          |               |
| Never use of private bathroom                | 2.06                | 1.05-4.04  | 2.32     | 1.18-4.57     |
| Urinary incontinence                         | 2.70                | 1.05-6.93  |          |               |
|  |                     |            |          |               |
| Previous exposure to ATB within 6 months     | 2.38                | 1.25-4.52  | 2.32     | 1.20-4.49     |
| Amoxicillin                                  | 2.40                | 1.00-5.79  |          |               |
| 3GC  | 2.33                | 0.97-5.56  |          |               |
| Previous hospitalization within 12 months    | 2.56                | 1.31-4.98  | 2.04     | 1.03-4.03     |

Table IV. Factors associated with ESBLE carriage from random-effects logistic regression analysis

HW: healthcare workers; GIR: level of dependency French index; ESBLE: extended-spectrum-beta-lactamase producing Enterobacteriaceae; CPE: carbapenemase-producing Enterobacteriacaea; ATB: antibiotics; 3GC: third generation cephalosporins; NH: nursing home; CI: confidence interval.